Clinical Trials & Research

Print this page 21 May 2020 — AstraZeneca is advancing its ongoing response to address the unprecedented challenges of COVID-19, collaborating with a number of countries and multilateral organisations to make the University of Oxford’s vaccine widely accessible around the world in an equitable manner. The Company has concluded the first agreements for at least

May 22 2020 Almost half of doctors in England (45%) report suffering from work-related anxiety, burnout and depression, with a third of those saying this has worsened during the Covid-19 pandemic, a recent BMA survey has revealed. In a paper published today, the BMA is calling for more support for doctors suffering with poor mental

Print this page Friday, May 15, 2020 — A single dose of ChAdOx1 nCoV-19, an investigational vaccine against SARS-CoV-2, has protected six rhesus macaques from pneumonia caused by the virus, according to National Institutes of Health scientists and University of Oxford collaborators. SARS-CoV-2 is the virus that causes COVID-19. The researchers posted their data to

Having now reached its third year, Project “iHEART” of Politecnico di Milano, winner of an ERC Advanced Grant of euro 2,350,000, has set itself the ambitious goal of creating a complete mathematical model to study the behavior of the human heart and of its pathologies, a sort of “virtual microscope.” This integrates all cardiac function

Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 18, 2020– Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced positive interim clinical data of mRNA-1273, its vaccine candidate against novel coronavirus (SARS-CoV-2), from the Phase 1 study led by

May 18 2020 Boehringer Ingelheim today announced the acquisition of Northern Biologics Inc., a wholly owned subsidiary of Northern LP. By acquiring this entity, which focuses on therapeutic antibodies targeting the tumor microenvironment, Boehringer Ingelheim is now positioned at the forefront of the stromal biology space – an emerging area in cancer immunology. The seller

Print this page SAN DIEGO, May 15, 2020 /PRNewswire/ – Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) announced today that its anti-SARS-CoV-2 antibody, STI-1499, demonstrated 100% inhibition of SARS-CoV-2 virus infection in an in vitro virus infection experiment at a very low antibody concentration. As recently announced, Sorrento aims to generate an antibody cocktail product that would act as a “protective shield”

Reviewed by Emily Henderson, B.Sc.May 15 2020 A team of anthropologists, physicians, tribal leaders and local government authorities developed and implemented a multi-phase COVID-19 prevention and containment plan among the Tsimane, an indigenous group of forager-horticulturists in the Bolivian Amazon. The collaborative effort is led by Hillard Kaplan, Ph.D., professor of health economics and anthropology

Print this page KENILWORTH, N.J.–(BUSINESS WIRE) May 13, 2020 –Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced first-time results from a Phase 2 trial evaluating the hypoxia-inducible factor-2 alpha (HIF-2α) inhibitor MK-6482, a novel investigational candidate in Merck’s oncology pipeline, for the treatment of von Hippel-Lindau (VHL) disease-associated clear

In a study published today (May 13, 2020) in the New England Journal of Medicine, scientists in the U.S. and Japan report that in the laboratory, cats can readily become infected with SARS-CoV-2, the virus that causes COVID-19, and may be able to pass the virus to other cats. Professor of Pathobiological Sciences at the

Print this page CAMBRIDGE, Mass.–(BUSINESS WIRE)–May 12, 2020– Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for the Company’s mRNA vaccine candidate (mRNA-1273) against the

As the COVID-19 pandemic rages in many parts of the world, a new study shows that smoking may not play a significant role in increasing the severity of illness in these patients. The study is published on the preprint server medRxiv* in May 2020. It is now well known that severe acute respiratory syndrome coronavirus

Print this page TEL-AVIV, Israel and RALEIGH, NC, May 8, 2020, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for a Phase 2a clinical study evaluating its investigational drug, opaganib (Yeliva®, ABC294640)1, in patients with

Reviewed by Emily Henderson, B.Sc.May 9 2020 In the ongoing struggle to address health care disparities in rural communities across the U.S., a recent Oregon State University study found that the perfect partner may be hiding in plain sight. The grange, founded in 1867 and officially titled the National Grange of the Order of Patrons

Print this page FOSTER CITY, Calif.–(BUSINESS WIRE)–May 7, 2020– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has granted regulatory approval of Veklury® (remdesivir) as a treatment for SARS-CoV-2 infection, the virus that causes COVID-19, under an exceptional approval pathway. The exceptional approval was granted due to the COVID-19 pandemic and

A Keele University academic is part of a team of researchers who are calling for the World Health Organisation (WHO) to change its official definition of the weak bone condition osteoporosis in order to increase consistency of diagnosis internationally and to also increase the uptake of treatment. Dr Zoe Paskins, a Senior Lecturer and Consultant

Print this page NEW YORK & MAINZ, Germany–(BUSINESS WIRE) May 5, 2020 –Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced today that the first participants have been dosed in the U.S. in the Phase 1/2 clinical trial for the BNT162 vaccine program to prevent COVID-19. The trial is part of a global development

Ben-Gurion University of the Negev (BGU) scientists have developed a new methodology to trace the SARS-CoV-2 virus through the sewage and wastewater systems, which could potentially be used to track existing and future outbreaks of the coronavirus. Environmental monitoring of sewage can be effective if clinical testing is deficient in ascertaining the infection rate. Sewage

Print this page FOSTER CITY, Calif.–(BUSINESS WIRE)–Apr. 29, 2020– Gilead Sciences. Inc. (Nasdaq: GILD) is aware of positive data emerging from the National Institute of Allergy and Infectious Diseases’ (NIAID) study of the investigational antiviral remdesivir for the treatment of COVID-19. We understand that the trial has met its primary endpoint and that NIAID will provide detailed

Kudos, the award-winning service for accelerating research impact, has today announced that it is opening up its leading research communications platform – Kudos Pro – to the global academic community, with complimentary access for 60 days. Over 2,000 researchers around the world have already signed up for complimentary access following an exclusive pre-launch. With campuses

Print this page FOSTER CITY, Calif.–(BUSINESS WIRE)–May 1, 2020– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for the investigational antiviral remdesivir to treat COVID-19. The EUA will facilitate broader use of remdesivir to treat hospitalized patients with severe COVID-19 disease, enabling access to remdesivir at

May 1 2020 Through serendipity, researchers at the University of Pittsburgh Graduate School of Public Health considerably reduced the toxicity of a potential antibiotic against the most feared drug-resistant bacteria, while also improving its stability in fighting infections. Image Credits: royaltystockphoto.com / Shutterstock.com The new antibiotic — administered via the windpipe to target lung infections

Print this page FOSTER CITY, Calif.–(BUSINESS WIRE)–Apr. 29, 2020– Gilead Sciences, Inc. (Nasdaq: GILD) today announced topline results from the open-label, Phase 3 SIMPLE trial evaluating 5-day and 10-day dosing durations of the investigational antiviral remdesivir in hospitalized patients with severe manifestations of COVID-19 disease. The study demonstrated that patients receiving a 10-day treatment course of remdesivir

Steady hands and uninterrupted, sharp vision are critical when performing surgery on delicate structures like the brain or hair-thin blood vessels. While surgical cameras have improved what surgeons see during operative procedures, the “steady hand” remains to be enhanced — new surgical technologies, including sophisticated surgeon-guided robotic hands, cannot prevent accidental injuries when operating close

Print this page DUBLIN and SOUTH SAN FRANCISCO, Calif., April 23, 2020 /PRNewswire/ – Theravance Biopharma, Inc. (NASDAQ: TBPH) (“Theravance Biopharma” or the “Company”), a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines, today announced that the first healthy volunteer has been dosed in a Phase 1 study of TD-0903. TD-0903 is a lung-selective, nebulized Janus

Print this page London, UK 23 April 2020 — GlaxoSmithKline plc today announced data from an updated analysis of the GARNET trial, which demonstrated that dostarlimab, an investigational anti-programmed death-1 (PD-1) monoclonal antibody, provided clinically meaningful results in women with recurrent or advanced mismatch repair-deficient (dMMR) endometrial cancer who progressed on or after a platinum-based

Reviewed by Emily Henderson, B.Sc.Apr 28 2020 Researchers at the Wyss Institute at Harvard University, in collaboration with healthcare, research, and industrial partners, have designed a new, fully injection-molded nasopharyngeal swab that can be manufactured quickly and inexpensively at high volume to help address the nationwide and international shortage of swabs for COVID-19 testing and

Print this page Paris and Tarrytown, N.Y. April 27, 2020 – Sanofi and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced the preliminary results from the Phase 2 portion of an ongoing Phase 2/3 trial evaluating Kevzara® (sarilumab), an interleukin-6 (IL-6) receptor antibody, in hospitalized patients with “severe” or “critical” respiratory illness caused by COVID-19. Following